VelaVigo Announces Exclusive Option Agreement with Avenzo to License a Potential First-in-Class Nectin4/TROP2 Bispecific Antibody-Drug...

LigaChem Biosciences receives near-term milestone payment for ‘LCB97’ from Japan’s Ono Pharmaceutical

Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time

FDA Fast Tracks ALE.P02 for CLDN1-Poisitive Solid Cancers

Pyxis Oncology Announces Favorable Preliminary PYX-201 Clinical Phase 1 Part 1 Data

AbbVie’s ELAHERE Receives EU Approval for Treating Platinum-Resistant Ovarian Cancer